Premium
Anti‐tumor activity of mesenchymal stem cells producing IL‐12 in a mouse melanoma model
Author(s) -
Elzaouk Lina,
Moelling Karin,
Pavlovic Jovan
Publication year - 2006
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/j.1600-0625.2006.00479.x
Subject(s) - mesenchymal stem cell , melanoma , cancer research , interleukin 12 , interleukin 15 , cytotoxic t cell , immunology , cd8 , cytokine , interleukin 21 , biology , interleukin , medicine , immune system , in vitro , microbiology and biotechnology , biochemistry
Mesenchymal stem cells (MSCs) represent a new tool for delivery of therapeutic agents to tumor cells. In this study, we have evaluated the anti‐tumor activity of human MSCs stably transduced with a retroviral vector expressing the cytokine interleukin‐12 (IL‐12) in a mouse melanoma model. Application of MSC(IL‐12) but not control MSCs strongly reduced the formation of lung metastases of B16F10 melanoma cells. The activity of the MSC(IL‐12) cells was dependent on the presence of natural killer (NK) cells in this experimental setting. Further, MSC(IL‐12) cells elicited a pronounced retardation of tumor growth and led to prolonged survival when injected into established subcutaneous melanoma in a therapeutic regimen. The therapeutic effect of the MSC(IL‐12) was in part mediated by CD8 + T cells, while NK cells and CD4 + T cells appeared to play a minor role. The anti‐tumor effect of MSC(IL‐12) cells was of similar efficiency as observed for application of naked plasmid DNA encoding IL‐12. The presented data demonstrate that these two different strategies can induce a similar therapeutic anti‐tumor efficacy in the mouse melanoma tumor model.